Skip to content

DeNovo NT Ankle LDC Study

Post Market, Longitudinal Data Collection Study of Articular Cartilage Lesions in the Ankle Treated With DeNovo(R) NT Natural Tissue Graft

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01347892
Enrollment
205
Registered
2011-05-05
Start date
2011-03-31
Completion date
2019-09-30
Last updated
2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Defect of Articular Cartilage, Osteochondral Lesion of Talus, Osteochondritis Dissecans

Keywords

Talar injury, ankle, lesion, defect, cartilage repair

Brief summary

The purpose of this post-market clinical study is to collect long-term outcomes for DeNovo NT Graft treatment of articular cartilage lesions in the ankle in a standard clinical setting. Outcomes to be assessed include pain, function, activity levels and healthcare resource use.

Detailed description

Articular cartilage lesions in the ankle can cause significant pain and loss of function for young to middle age adults. There are several treatment options for symptomatic articular cartilage injuries depending on a patient's age, symptoms and duration of complaints in addition to the size and condition of the lesion. DeNovo NT Natural Tissue Graft is comprised of fresh particulated juvenile cartilage pieces that are secured inside articular cartilage lesions using fibrin adhesive. DeNovo NT Graft was developed due to the current need for expanded treatment options for the treatment of cartilage lesions, especially large lesions. This post-market, multicenter, longitudinal data collection study was established to collect clinical outcomes of subjects implanted with DeNovo NT Graft. Data may be obtained either retrospectively or prospectively from patients implanted or to be implanted with DeNovo NT Graft for the treatment of lesion in the ankle. Data to be collected include details of the operative procedure as well as subject pain, function, activity levels, and healthcare resource use through a five year post-operative follow-up period.

Interventions

OTHERDeNovo NT Natural Tissue Graft

DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each

Sponsors

Zimmer Orthobiologics, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Potential subjects are screened for study entry based on a preliminary review of the inclusion and

Exclusion criteria

as it applies to their pre-operative status (unless otherwise noted). Inclusion Criteria: * Has an articular cartilage lesion(s) in the ankle for which arthroscopic or surgical intervention with DeNovo NT Graft is warranted or has had prior treatment with DeNovo NT Graft for an articular cartilage lesion(s) in the ankle * Has voluntarily signed the IRB approved informed consent * Is of stable health and is able to undergo surgery * Is male or female over the age of 18 at the time of consent * Is physically and mentally willing and able to comply with post-operative rehabilitation and routinely scheduled clinical visits.

Design outcomes

Primary

MeasureTime frame
Mean scores from patient-reported clinical outcome surveys5 years

Secondary

MeasureTime frame
Incidence of reoperations and revision surgeries5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026